Synergy Pharma (Nasdaq: SGYP) announced the presentation of results from a phase 2b dose-ranging study assessing plecanatide’s safety and efficacy ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE